Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Simulations Plus to Present at Raymond James Institutional Investors Conference: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus to Present at Raymond James Institutional Investors Conference


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting

Kezar Life Sciences to Participate in Cowen 42nd Annual Health Care Conference
Kezar Life Sciences to Participate in Cowen 42nd Annual Health Care Conference


Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that

Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus (RSV) Vaccine Candidate for the Prevention of RSV in Infants from Birth up to Six Months of Age by Active Immunization of Pregnant Women http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus (RSV) Vaccine Candidate for the Prevention of RSV in Infants from Birth up to Six Months of Age by Active Immunization of Pregnant Women


Pfizer Inc. (NYSE:PFE) today announced that its respiratory syncytial virus (RSV) vaccine candidate, PF-06482077 or RSVpreF, received Breakthrough Therapy Designation from the US Food and Drug

NanoString Technologies Releases Fourth Quarter and Full Year 2021 Operating Results and Provides 2022 Financial Outlook: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString Technologies Releases Fourth Quarter and Full Year 2021 Operating Results and Provides 2022 Financial Outlook


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the fourth quarter and year

FDA Grants Breakthrough Device Designation for Dexcom Hospital CGM System: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
FDA Grants Breakthrough Device Designation for Dexcom Hospital CGM System


DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the FDA has granted Breakthrough Device Designation for

Premier, Inc. to Participate in Upcoming Investor Conferences: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. to Participate in Upcoming Investor Conferences


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, announced today that members of its management team are scheduled to participate in the following investor

Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpointshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints


Pfizer Inc. (NYSE:PFE) today announced results from the CLOVER trial (CLOstridium difficile Vaccine Efficacy TRial), a pivotal Phase 3 study evaluating its Clostridioides difficile (C. difficile)

Quidel to Present at Raymond James 43rd Annual Institutional Investors Conference
Quidel to Present at Raymond James 43rd Annual Institutional Investors Conference


Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences:




  • Cowen 42nd Annual Health Care

Acadia Healthcare Reports Fourth Quarter 2021 Results: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Reports Fourth Quarter 2021 Results


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the fourth quarter and year ended December 31, 2021.



Fourth Quarter Highlights




  • Revenue totaled $593.5

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conferencehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Angela Hwang, Group President, Pfizer Biopharmaceuticals Group; Andy Schmeltz

Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine Meeting: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine Meeting


Clovis Oncology, Inc. (NASDAQ: CLVS) today announced a Trial-in-Progress poster detailing the Phase 1 portion of the LuMIERE clinical study for its targeted radiotherapy candidate FAP-2286 and a

Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported fourth quarter and full year 2021 financial results and recent business highlights.



“In 2021, we continued

Novocure’s General Counsel Resigns After 10 Years of Service: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure’s General Counsel Resigns After 10 Years of Service


Novocure (NASDAQ: NVCR) today announced that Todd Longsworth, General Counsel, has resigned. Mr. Longsworth’s last day as General Counsel will be March 31. He will stay onboard as a Senior Legal

NanoString to Webcast Presentation from the 42nd Annual Cowen Health Care Conference: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString to Webcast Presentation from the 42nd Annual Cowen Health Care Conference


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a

Chemed Reports Fourth-Quarter 2021 Results:
Chemed Reports Fourth-Quarter 2021 Results


Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest

Agilent to Participate at Cowen and Barclays Health Care Conferences:
Agilent to Participate at Cowen and Barclays Health Care Conferences


Agilent Technologies Inc. (NYSE: A) today announced that Bob McMahon, senior vice president and chief financial officer, will participate in Q&A sessions at the Cowen 42nd Annual Health Care

Agilent and University of Vermont Announce the Agilent Laboratory for Chemical Analysis (ALCA):
Agilent and University of Vermont Announce the Agilent Laboratory for Chemical Analysis (ALCA)


Agilent Technologies Inc. (NYSE: A) and the University of Vermont (UVM) today announced the establishment of the Agilent Laboratory for Chemical Analysis (ALCA). The facility will be a hub for

New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response


Novocure (NASDAQ: NVCR) today announced that a new study published in the Journal of Clinical Investigation (JCI) finds treatment with Tumor Treating Fields (TTFields) mediated cell disruption

Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update


Novocure (NASDAQ: NVCR) today reported financial results for the fourth quarter and full year ended December 31, 2021. Novocure is a global oncology company working to extend survival in some of

Xencor Reports Fourth Quarter and Full Year 2021 Financial Results: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Reports Fourth Quarter and Full Year 2021 Financial Results


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial

STAAR Surgical Reports Fourth Quarter and Full Year 2021 Results: https://mms.businesswire.com/media/20200413005098/en/683092/5/STAAR_Surgical_Logo_Primary_Lockup_%28Sunise_Teal%29.jpg
STAAR Surgical Reports Fourth Quarter and Full Year 2021 Results


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the

Cole Edmonson of AMN Healthcare Honored as Staffing Industry Leader, Named to SIA Staffing 100
Cole Edmonson of AMN Healthcare Honored as Staffing Industry Leader, Named to SIA Staffing 100


Cole Edmonson, Chief Clinical Officer of AMN Healthcare (NYSE: AMN), has been honored as one of Staffing Industry Analysts’ 2022 Staffing 100, the leaders of the staffing industry.



The Staffing

Published Study Details Proof-of-Concept for COVID-19 Detection via Saliva Screening:
Published Study Details Proof-of-Concept for COVID-19 Detection via Saliva Screening


Agilent Technologies Inc. (NYSE: A) announced today that researchers from the QIMR Berghofer Medical Research Institute in Brisbane, Australia, collaborated with Agilent experts on a

Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones


Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended December 31, 2021, and provided an update on the Company’s clinical development programs and regulatory and